October 2020 Vol 11, No 10

Did you attend our virtual Midyear Conference in May? It was an incredible event! At first, the thought of switching our usual in-person conference to a virtual one was a bit disappointing to me. But there were several elements of that experience that made the virtual conference one of my all-time favorites.

The authors report results from their prospective study of the effect of a patient navigation program on distress and health-related quality of life.

Osimertinib in the adjuvant treatment setting significantly improves disease-free survival (DFS) in patients with localized non–small-cell lung cancer (NSCLC) with an epidermal growth factor receptor (EGFR) mutation.

A strong screening program can make a big difference. Here are tips for your program from the Maine Lung Cancer Coalition.

For some patients, the use of CAR-T cell therapy has resulted in robust and durable (>95%) responses lasting longer than 5 years. Here’s what you need to know about CAR T-cell therapy.

What you need to know about lessening the burden of a metastatic diagnosis.

Fertility preservation is a time-sensitive and logistic-heavy process. Are you having the right conversations with your patients?

With a follow-up of >5 years, women with relapsed platinum-sensitive ovarian cancer and a BRCA mutation who participated in the multicenter phase 3 SOLO2 trial lived >1 year longer if randomized to maintenance olaparib compared with placebo, according to data released at the ASCO20 Virtual Scientific Program.

Learn how to assess and recognize distress in your patients – and what you can do about it.

Presenting the concept of the tumor board to your patient and acting as their representative.

There’s a new standard of care in the first-line setting for a subset of patients with advanced colorectal cancer.